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ABSTRACT 
Microbubbles designate air or gas filled microspheres 
suspended in a liquid carrier phase which generally results 
from the introduction of air or gas. The liquid phase 
contains surfactants to control the surface properties as well 
as stability of the bubble. Microbubbles have an average 
size less than that of RBC’s i.e. they are capable of 
penetrating even into the smallest blood capillaries & 
releasing drugs or genes, incorporated on their surface, 
under the action of ultrasound. Microbubbles in general 
have a wide variety of applications. However in the 
biomedical field these are primarily used as diagnostic 
agents in combination with ultrasound for molecular 
imaging of various organs and even tumors. These are also 
proposed for drug and gene delivery to targeted regions in 
combination with various ligands. Most of the physicians 
today prefer imaging with ultrasound in combination with 
microbubbles compared to other diagnostic techniques for 
low cost and rapidity. 
 
KEYWORDS: Microbubbles, diagnostic agents, 
ultrasound, drug delivery, gene delivery, ligands. 
 
 
 
 
INTRODUCTION
1
: 
Microbubbles are also small spherical bubbles comprising 
of gas, they remain distinct from each other or separate 
from each other i.e. do not agglomerate, also they have 
their size range in micrometers usually 1-100 µm. There 
has been a lot of research on micro bubbles in recent years.  
Micro bubbles are miniature gas bubbles of less than 50 
microns diameter in water. The micro bubbles, which 
mostly contain oxygen or air, can remain suspended in the 
water for an extended period. Gradually, the gas within the 
micro bubbles dissolves into the water and the bubbles 
disappear. 
In the medical field microbubbles have been used as 
diagnostic aids to scan the various organs of body and 
recently they are being proposed to be used as drug or gene 
carriers and also for treatment in cancer therapy. 
Microbubbles have been used in a variety of fields , these 
have been used to improve the fermentation of soil, used to 
increase the hydroponic plant growth, have been to used to 
increase the aquaculture productivity, these have been also 
used to improve the quality of water, used in sewage 
treatment .  
Biomedically microbubbles are defined as small spherical 
gas bubbles made up of phospholipids or biodegradable 
polymers, that are approximately the size of RBC’s and are 
used as diagnostic aids, as drug and gene carriers in 
combination with ultrasound. 
PROPERTIES OF MICROBUBBLES 
1
: 
The ideal properties of microbubbles can be divided into 
two classes, 
1) Functional Properties 
2) Structural Properties 
 
1) Functional Properties: 
The functional properties are those which render them 
useful for performing their various functions these include, 
a)  Injectability: 
Since these microbubbles are to be injected into the body so 
as to exert their various actions they should be injectable. 
b)  Ultrasound Scattering Efficiency: 
As these microbubbles act in combination with ultrasound 
they should have ultrasound scattering efficiency.  
c)  Biocompatibility: 
Microbubbles interact with the vital organs of the body at 
cellular levels they should be biocompatible. 
 
2)  Structural Properties: 
These refer to the structure or the physical properties of the 
microbubbles, these are as follows, a)  should have an 
average external diameter between the ranges of 1-10 µm, 
narrow size distribution so as to avoid complications when 
injected into the body 
b)  density & compressibility difference between 
themselves & the surrounding body tissues to create an  
acoustic impedance & to scatter ultrasound at a much 
higher intensity than the body tissues so as to be used as 
contrast agents 
c)  sufficient surface chemical properties to be modified for 
the attachment of various ligands to target them to specific 
tissues or organs 
d)  uniformity of shell thickness 
 
 
 
COMPONENTS OF MICROBUBBLES
1,2,3,4
: 
Microbubbles basically comprise of three phases  
1)  Innermost   Gas Phase 
2)  Shell Material Enclosing the Gas Phase 
3)  Outermost Liquid or Aqueous Phase 
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In addition to this the formulation may also comprise of various other components. 
 
FIG.1 : Components of Microbubbles 
 
1) GAS PHASE: 
The gas phase can be a single gas or a combination of gases 
can be used. Combination gases are used to cause 
differentials in partial pressure & to generate gas osmotic 
pressures which stabilize the bubbles.  
When a combination of gases is used two types of gases are 
involved one is the Primary Modifier Gas also known as 
first gas. Air is preferably used as primary modifier gas, 
sometimes nitrogen is also used as first gas. The vapor 
pressure of first gas is (760 - x ) mm of Hg , where x is the 
vapor pressure of the second gas. 
The other gas is Gas Osmotic Agent also known as second 
gas; it is preferably a gas that is less permeable through the 
bubble surface than the modifier gas. It is also preferable 
that the gas osmotic agent is less soluble in blood & serum. 
Gas osmotic agent is normally a gas at room temperature or 
liquid so long as it has a sufficient partial or vapor pressure 
at the temperature of use to provide the desired osmotic 
effect. Some examples of second gas are per fluorocarbons 
or sulfur hexafluoride. 
 
 
2) SHELL MATERIAL: 
The shell material encapsulates the gas phase. It plays a 
major role in the mechanical properties of microbubble as 
well as diffusion of the gas out of the microbubble. The 
shell also acts a region for encapsulation of drug molecules 
also ligands can be attached to the shell membrane so as to 
achieve targeting of these microbubbles to the various 
organs or tissues. It accounts for the elasticity or 
compressibility of microbubbles.  
More elastic the shell material is more acoustic energy it 
can withstand before bursting or breaking up, this increases 
the residence time of these bubbles in body.  
More hydrophilic the shell material, more easily it is taken 
up by the body this decreases the residence time of these 
bubbles in the body.  
 
Eg: The various types of shell materials that can be used 
are  
           Proteins like albumin 
           Carbohydrates like galactose 
            Phospholipids  like phosphotidylcholine, 
phosphotidylethanolamine etc.  
            Biodegradable  polymers like polyvinyl alcohol, 
polycaprolactone etc. 
 
3) AQUEOUS OR LIQUID PHASE: 
The external, continuous liquid phase in which the bubble 
resides typically includes a surfactant or foaming agent. 
Surfactants suitable for use include any compound or 
composition that aids in the formation & maintenance of 
the bubble membrane by forming a layer at the interphase. 
The foaming agent or surfactant may comprise a single 
component or any combination of compounds, such as in 
the case of co surfactants. 
Also the persistence of microbubble in body is inversely 
proportional to La Place pressure which in turn is directly 
proportional to surface tension of bubble. In other words 
decrease in the surface tension acting on the bubble 
increases the persistence time of the bubble in the body.  
Eg: Block copolymers of polyoxypropylene, 
polyoxyethylene, sugar esters, fatty alcohols, aliphatic 
amine oxides, hyaluronic acid esters & their salts, dodecyl 
poly  (ethyleneoxy ) ethanol, etc. 
Nonionic Surfactants:  Polyoxyehylene polyoxypropylene 
copolymers Eg. Pluronic F-68, polyoxyethylene stearates, 
polyoxyethylene fatty alcohol ethers, polyoxyethylated 
sorbitan fatty acid esters, glycerol polyethylene glycol 
oxystearates, glycerol polyethylene glycol ricinoleate etc. 
Anionic Surfactants: Fatty acids having 12 -24 carbon 
atoms Eg. Sodium Oleate. 
 
4) OTHER COMPONENTS: 
The various other components that may be incorporated in 
the formulation include osmotic agents, stabilizers, 
chelators, buffers, viscosity modulators, air solubility 
modifiers, salts & sugars can be added to fine tune the 
microbubble suspensions for maximum shelf life & 
contrast enhancement effectiveness. Such considerations as 
sterility, isotonicity   & biocompatibility may govern the 
use of such conventional additives to injectable 
compositions.  
 
METHODS TO PREPARE MICROBUBBLES: 
The various methods that can be used for the preparation of 
these microbubbles include: 
1) Cross Linking Polymerization 
2) Emulsion Solvent Evaporation 
3) Atomization & Reconstitution 
4) Sonication 
 
1) CROSS LINKING POLYMERISATION5: 
In this a polymeric solution is vigorously stirred, which 
results in the formation of a fine foam of the polymer 
which acts  as a colloidal stabilizer as well as a bubble 
coating agent. The polymer is then cross linked, after cross 
linking microbubbles float on the surface of the mixture. 
Floating microbubbles are separated & extensively dialyzed 
against Milli Q water. 
Eg: 2% aqueous solution of telechelic PVA is vigorously 
stirred at room temperature for 3 hrs at a pH of 2.5 by an 
Ultra Turrax T-25 at 8000 rpm equipped with a teflon 
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coated tip, fine foam of PVA is formed. The PVA is then 
cross linked at room temperature and at 5οC by adding HCl 
or H2SO4 as a catalyst, the cross linking reaction is stopped 
by neutralization of the mixture and microbubbles are then 
separated. 
 
2) EMULSION SOLVENT EVAPORATION6: 
In this method two solutions are prepared, one is an 
aqueous solution containing an appropriate surfactant 
material which may be amphilic biopolymer such as 
gelatin, collagen, albumin or globulins. This becomes the 
outer continuous phase of the emulsion system. 
The second is made from the dissolution of a wall forming 
polymer in a mixture of two water immiscible organic 
liquids. One of the organic liquids is a relatively volatile 
solvent for the polymer & the other is relatively nonvolatile 
nonsolvent for the polymer. 
The polymer solution is added to the aqueous solution with 
agitation to form an emulsion. The emulsification step is 
carried out until the inner phase droplets are in the desired 
size spectrum. It is the droplet size that will determine the 
size of the microbubble. 
As   solvents   volatilizes,   polymer conc. in the droplet 
increases to a point where it precipitates in the presence of 
the less volatile nonsolvent.  This process forms a film of 
polymer at the surface of the emulsion droplet. As the 
process continues, an outer shell wall is formed which 
encapsulates an inner core of nonsolvent liquid. Once 
complete, the resulting microcapsules can then be retrieved, 
washed & formulated in a buffer system.   Subsequent 
drying, preferably by freeze-drying, removes both the 
nonsolvent organic liquid core & the water to yield air 
filled hollow microbubbles. 
 
3)  ATOMISATION & RECONSTITUTION: 
A   spray dried surfactant solution is formulated by 
atomizing a surfactant solution into a heated gas this results 
in formation of porous spheres of the surfactant solution 
with the primary modifier gas enclosed in it. These porous 
spheres are then packaged into a vial, the headspace of the 
vial is then filled with the second gas or gas osmotic agent. 
The vial is then sealed, at the time of use it is reconstituted 
with a sterile saline solution. Upon reconstitution the 
primary modifier gas diffuses out & the secondary gas 
diffuses in, resulting in size reduction. The microbubbles so 
formed remain suspended in the saline solution & are then 
administered to the patient.  
          
 
 
 
 
 
                        
4) SONICATION: 
 
 
Sonication is preferred for formation of microbubbles, i.e. 
through an ultrasound transmitting septum or by 
penetrating a septum with an ultrasound probe including an 
ultrasonically vibrating hypodermic needle. Sonication can 
be accomplished in a number of ways, for eg. A vial 
containing a surfactant solution & gas in headspace of the 
vial can be sonicated through a thin membrane. Sonication 
can be done by contacting or even depressing the 
membrane with an ultrasonic probe or with a focused 
ultrasound “beam”. Once sonication is accomplished, the 
microbubble solution can be withdrawn from the vial & 
delivered to the patient. 
Sonication can also be done within a syringe with a low 
power ultrasonically vibrated aspirating assembly on the 
syringe. 
CHARACTERISATION OF MICROBUBBLES6: 
Once prepared these microbubbles are characterized as per 
the following parameters, 
1) Microbubble Diameter & Size Distribution:  
The average diameter as well as size distribution of these 
microbubbles can be determined by Laser light Scattering, 
Scanning Electron Microscopy, Transmission Electron 
Microscopy. 
2) Shell Thickness: 
Shell thickness is determined by coating the shell with a 
fluorescent dye like Red Nile, this is then determined by 
Fluorescent Microscopy against a dark background. 
3) Microbubble Concentration: 
The microbubble concentration is determined by counting 
the no. of microbubbles per ml by using the Coulter 
Counter Machine. 
4) Air Content by densitometry: 
The content of air encapsulated within the microbubbles in 
the suspension samples is measured by oscillation U-tube 
densitometry with a DMA-58. The instrument is calibrated 
Reconstitution with     
sterile saline 
solution 
Lyophilised or  
Spray dried 
powder 
 
 FIG.2  
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with air and purified water prior to use. The density of the 
suspension is measured before and after elimination of 
encapsulated air. The complete removal of encapsulated air 
is achieved by 5 min high powered sonication in a 
sonicator. 
The air content is calculated as,   
Cair = ρ1 –ρ2/ρ2 *100 
Where, Cair is air content (%v/v) 
ρ1 (g/ml) density before elimination of encapsulated air 
ρ2 (g/ml) density after elimination of encapsulated air 
 
5) Ultrasound Reflectance Measurement: 
Experimental set up consists of transducer, microbubble 
contained in a vessel consisting of metallic reflector and 
cellophane membrane, this vessel is in turn kept in another 
vessel containing water. The signals which are reflected are 
evaluated for the ultrasound reflecting capacity of these 
microbubbles.
 
BIOMEDICAL APPLICATIONS
7,8,9,10
: 
1) DIAGNOSTIC AIDS: 
Microbubbles are elastic and compressible, these undergo 
compression and rarefaction thereby creating an acoustic 
impedance mismatch between biological tissues and fluids 
as these are efficient reflectors of ultrasound, hence used as 
contrast agents 
  
 
FIG.3 : Non Linear Behaviour 
Microbubbles Undergoing Compression 
And Rarefaction  
These are used as diagnostic aids for:  
1) Organ Edge Delineation 
2) Blood Volume and Perfusion                                             
3) Inflammation 
4) Cancer 
5) Liver 
6) Also used to scan the tumors arising in the body. 
7) Used for imaging the gall bladder stone. 
                        
 
FIG.4 : Ultrasound Scan Of Liver 
Using Levovist 
ADVANTAGES: 
1) Inexpensive as compared to other diagnostic 
agents. 
2) No use of ionizing radiation. 
3) Faster and accurate as compared to other 
diagnostic techniques. 
        DRUG DELIVERY
11,12,13,14
: 
On application of low frequency ultrasound, these 
microbubbles start oscillating & undergo a process of 
cavitation resulting in bursting or break up of the 
bubble, drug molecules if incorporated within the 
bubble are released by this process & these are useful 
in drug delivery. 
Two factors which are taken into account for drug 
delivery are: 
1) Incorporation of drug into these microbubbles 
2) Drug release from these microbubbles 
1) Incorporation of drug into microbubbles: 
Drug molecules can be incorporated in a variety of 
ways within the microbubble as follows, 
a. Drug molecules can be incorporated within the 
bubble 
b. Drug molecules can also be incorporated within the 
bubble membrane or shell material of the 
microbubble. 
c. Drugs can also be attached to the shell of the 
microbubble (for eg. by noncovalent bonds) 
d. These can also be attached to the microbubble 
surface via a ligand (for eg. avidin-biotin complex). 
e. Also if the microbubble is made up of multiple 
layers it can also be incorporated within the various 
layers  of these microbubble. 4. These microbubbles 
are proposed to cross the blood brain barrier. 
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FIG.5 : Incorporation of drug into 
Microbubbles 
 
Targeted microbubbles are created by attaching a 
targeting ligand (such as a monoclonal antibody or a 
peptide) specific for the desired (endothelial) marker 
onto the shell of the microbubbles. Targeted 
ultrasound contrast agents have been used to assess 
vascular pathology associated with several 
intravascular markers, including P-selectin, ICAM-1, 
 GpIIb/IIIa, the  αv integrins and other markers of 
tumor angiogenesis. 
 
2) Drug release from microbubbles:  
Microbubbles are also proposed to be carriers to be 
used in drug delivery. Microbubbles on application of 
ultrasound undergo a process known as cavitation 
which results in bursting or breakup of the 
microbubble on application of ultrasound. 
On cavitation the body fluids start insonating creating 
acoustic cavitation. Further as the microbubbles 
oscillate  they then give rise to small eddies, these 
eddies give rise to micro streaming or micro jets 
resulting in increase in permeability of the cell 
membrane & facilitating drug transfer across the 
membrane. Sometimes the microbubbles may also be 
phagocytosed by the cell membrane resulting in drug 
release. 
 
Another possible mechanism is fusion of the 
phospholipid microbubble with the phospholipid 
bilayer of cell membrane resulting in delivery of the 
drug or genes directly into the cytoplasm of the cell 
membrane. This is the proposed mechanism for gene 
delivery as it transfers the gene in close proximity of 
the nucleus.  
        The following figure shows drug delivery via the         
         microbubbles 
a. Drug delivery by cavitation 
b. Drug release by cavitation as well as increasing the 
permeability of cell membrane 
c. Phagocytosis of the microbubble by cell membrane 
d. Fusion of microbubble with the cell membrane 
 
 
    FIG.6 : Drug delivery via Microbubbles 
ADVANTAGES OF USING MICROBUBBLE FOR 
DRUG DELIVERY: 
1.  Since the microbubble delivers the drug in 
proximity to its target smaller dose of the drug is 
required as compared to conventional. 
2.  Also since the drug is released near its target & due 
to the small dose a decrease in the side effects is 
noticed especially for antineoplastic drugs. 
3.  By attaching various ligands these can be used for 
targeted drug delivery. 
 
 
FIG.7 : Drug Release From Microbubbles 
By Cavitation 
 
 
GENE DELIVERY
15
: 
The next most promising application of these 
microbubbles is these can be used as tools for gene 
delivery. The salient features of these microbubbles 
which make them useful for gene delivery are as 
follows: 
1. Microbubbles are metabolically inert  
2. When injected into the body the do not produce any 
immune response 
3. Also the gene encapsulated or attached to the 
microbubble is carried to its target without getting 
digested by the various enzymes. 
FIG.8 
JPRHC 
 Review Article 
 
JPRHC                                       VOLUME 2                                             ISSUE 3                                                          228-234 
Charged drugs can be stabilized in or onto the surfaces 
of microbubbles by virtue of electrostatic interactions 
lipid-coated microbubbles to bind DNA. DNA, 
because of the sugar phosphate groups in the 
molecule, is a polyanion (i.e. negatively charged). 
DNA is avidly bound to cationic (positively charged) 
microbubbles. The gene is released when ultrasound 
energy cavitates the microbubble. 
 
     Fig:8 Ultrasound Scan Of Liver Using    
      Levovist Microbubbles 
 
 
 
 
 
 
 
 
 
CONCLUSION: 
The application of microbubble with ultrasound which 
gives a synergistic effect for drug/DNA delivery is 
currently in its infancy. The use of targeted 
microbubbles is a great step forward and has created 
various challenging therapeutic options, not only in 
cardiovascular disease but also in treatment of 
inflammatory and malignant diseases  
Microbubbles have rapidly evolved from a diagnostic 
adjuvant to a possible therapeutic agent. In the coming 
years, this promising technique needs further 
development to make it available for clinical 
applications. 
 
FUTURE PERSPECTIVES: 
The use of microbubbles as a tool for drug delivery 
enhancement has an enormous clinical potential, 
especially in oncology and vascular applications. 
Whereas free drugs often possess harmful side effects, 
their encapsulation in microbubbles and subsequent 
local release, deposition, and potentiation in the target 
tissue by ultrasound triggering will help improve the 
therapeutic index, lower the incidence of adverse 
events, and achieve successful therapy. Microbubbles 
combined with ultrasound offer a possibility to 
optimize the action of the currently approved drugs 
and drug delivery systems by improving their 
pharmacokinetics and delivery to the target
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